Aspirin has been shown to reduce coronary artery disease mortality in
randomised placebo controlled trials quite convincingly. However is
this effect related to its preventing thrombus formation during acute
plaque fissuring in acute coronary syndromes or does it have any
effect on the chronic stable plaque? If the effect is only on the
fissured plaque, which is a one time event does it justify consuming
it daily? Would it be ethically justified to have a trial of aspirin
to patients administered only during episodes of sustained chest pain
and not on a regular basis?
Rakesh Biswas MD
Associate professor,
Dept of Internal Medicine,
Vydehi Institute of Medical Sciences and Research Centre (VIMSARC)
Whitefield, Bangalore, India. PIN-560066
Phone: 0091-80-8412956, mob: 9845509341
Fax- 0091-80-28416199
Email: [log in to unmask]
http://www.vims.ac.in/
|